Navigation Links
FDA Decision Encourages Lamictal Generics

As the FDA cannot approve an abbreviated new drug application (ANDA) for a listed drug that has been withdrawn due to reasons of safety or efficacy// , the agency had to determine the reasons for the withdrawal before approving any generic version.

The investigation found no evidence of safety or efficacy issues, and the FDA has announced that it can approve ANDAs provided all other legal and regulatory requirements are met. The FDA added that the ruling was in response to a citizen's petition from a patent attorney that was filed in June 1995.

However, even if rival drug makers were to file an application for the drug, the respective company could still face a patent suit from Glaxo as the patent in the US is not due to run out until 2009. Lamictal already faces generic competition in Europe, where its patents have expired.

Lamictal (lamotrigine) is an antiepileptic drug indicated as adjunctive therapy for partial seizures in adults and pediatric patients. It is also approved for conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug or valproate. In addition, Lamictal is indicated for the maintenance treatment of bipolar I disorder in certain patients.

Source-Bio-Bio Technology
'"/>




Page: 1

Related medicine news :

1. Decision making made easier
2. Decision making made easier
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
5. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
6. HRT: A Difficult Decision
7. Decisions On End-of-Life Treatment Found To Vary From Country To Country
8. Pharma Companies May Influence The Decisions Of Medical Students
9. Critical Decisions Have To Be Taken By Mothers Of Premature Babies
10. Novel Study Unravels a New Dimension to Decision Making
11. Distinct Brain Sections Are Activated While Making Risky Decisions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... addition of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered ... of every IT system, from the datacenter to the cloud to the edge. ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs ... hospitals and health systems in the nation and help their organizations navigate the ... organizations and been instrumental in developing successful hospital and health system strategy. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology: